Northland Securities Initiates Zynex(ZYXI.US) With Buy Rating, Announces Target Price $12.5
Zynex Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $16 Price Target
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed for Zynex on FDA Clearance and Solid Growth Prospects
Zynex Price Target Cut to $12.00/Share From $15.00 by RBC Capital
Zynex Analyst Ratings
RBC Capital Maintains Zynex(ZYXI.US) With Buy Rating, Cuts Target Price to $12
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Cuts Target Price to $16
Buy Rating Affirmed for Zynex Amid Growth and Strategic Innovations
Zynex Analyst Ratings
RBC Capital Reiterates Outperform on Zynex, Maintains $15 Price Target
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)
RBC Capital Reaffirms Their Buy Rating on Zynex (ZYXI)
Zynex Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Zynex, Maintains $21 Price Target
Maintaining Buy Rating for Zynex on Strong Growth and Positive Outlook
RBC Capital Remains a Buy on Zynex (ZYXI)
Zynex (ZYXI) Receives a Buy From RBC Capital